Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.
Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.
复制标题
通过 SELDI 质谱法进行血清蛋白分析：检测肾癌患者血清淀粉样蛋白 α 的多种变体。
DOI：
10.1016/s0022-5347(05)60173-5
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
F. Marshall
中科院分区：
文献类型：
--
作者：
F. Marshall
背景资料。为了评价循环肾细胞癌(RCC)细胞的存在在转移发展中的意义，作者扩展了先前的一项研究，以量化与转移模式相关的Cad-6mRNA水平。方法：检测66例RCC患者外周血中Cad-6mRNA的水平，包括55例新诊断的RCC患者(43例无转移，12例有转移)和11例复发的RCC患者。为了进行定量聚合酶链式反应分析，在25名健康志愿者的血液样本中确定了一个临界值，并在5名健康对照和10名其他恶性肿瘤患者的样本中进行了验证。分析转移部位与钙粘素-6mRNA水平之间的相关性，并进行随访研究(中位数为39个月)，以追踪患者接受肾切除术后的后续转移。结果。有转移者中69.9%阳性，无明显转移者中34.9%阳性(P<0.0099)。在复发肾癌患者中，仅有肺转移的患者阳性率(25.0%)显著低于有远处转移的患者(85.7%；P 0.044)。在43例新诊断的肾癌患者中，15例钙粘素-6阳性的患者中有5例在肾切除术后发生转移，而在28例钙粘素-6阴性的患者中仅有2例复发(P<0.0398)。此外，Cad-6阳性患者的无复发生存率明显低于Cad-6阴性患者(P<0.062)。结论外周血中Cad-6m RNA的定量可能是预测当前和未来转移的重要指标。然而，随后的转移并不总是与钙粘素-6mRNA的水平相关。这可能是由于循环中的肿瘤细胞数量较少，或者是由于循环中的肿瘤细胞中存在低水平的钙粘蛋白-6mRNA所致。
BACKGROUND. To evaluate the significance of the presence of circulating renal cell carcinoma (RCC) cells in the development of metastases, the authors extended a previous study to quantify cadherin-6 mRNA levels in association with the pattern of metastasis.METHODS. Cadherin-6 mRNA levels were measured in peripheral blood samples from 66 patients with RCC, including 55 patients who had newly diagnosed RCC (43 without metastases and 12 with metastases) and 11 patients who had recurrent RCC. For quantitative polymerase chain reaction analysis, a cutoff value was determined in blood samples from 25 healthy volunteers and was verified in samples from 5 healthy controls and from 10 patients who had other malignancies. The correlation between the site of metastases and the cadherin-6 mRNA level was analyzed, and a follow-up study (median, 39 months) to track subsequent metastases was performed after patients underwent nephrectomy. RESULTS. Cadherin-6 was found in 69.9% of patients with metastases and in 34.9% of patients without apparent metastases (P 0.0099). In the group of patients with recurrent RCC, patients who had only pulmonary metastases had a significantly lower positivity rate (25.0%) compared with patients who had distant metastases (85.7%; P 0.044). Among 43 patients with newly diagnosed RCC, 5 of 15 patients who were positive for cadherin-6 had metastases after nephrectomy, whereas only 2 of the 28 patients with negative cadherin-6 status had recurrent disease (P 0.0398). In addition, the recurrence-free survival of patients who were positive for cadherin-6 was poorer compared with the survival of patients who were negative for cadherin-6 (P 0.062).CONCLUSIONS. The quantification of cadherin-6 mRNA in peripheral blood may be a significant predictive marker for current and future metastases. However, subsequent metastases did not always correlate with levels of cadherin-6 mRNA. This may have been due either to the small numbers of circulating tumor cells or to the low levels cadherin-6 mRNA in circulating tumor cells.